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Sepsis is caused by a heterogeneous group of infectious etiologies. Early diagnosis and the provision of
appropriate antimicrobial therapy correlate with positive clinical outcomes. Current microbiological tech-
niques are limited in their diagnostic capacities and timeliness. Multiplex PCR has the potential to rapidly
identify bloodstream infections and fill this diagnostic gap. We identified patients from two large academic
hospital emergency departments with suspected sepsis. The results of a multiplex PCR that could detect 25
bacterial and fungal pathogens were compared to those of blood culture. The results were analyzed with respect
to the likelihood of infection, sepsis severity, the site of infection, and the effect of prior antibiotic therapy. We
enrolled 306 subjects with suspected sepsis. Of these, 43 were later determined not to have infectious etiologies.
Of the remaining 263 subjects, 70% had sepsis, 16% had severe sepsis, and 14% had septic shock. The majority
had a definite infection (41.5%) or a probable infection (30.7%). Blood culture and PCR performed similarly
with samples from patients with clinically defined infections (areas under the receiver operating characteristic
curves, 0.64 and 0.60, respectively). However, blood culture identified more cases of septicemia than PCR
among patients with an identified infectious etiology (66 and 46, respectively; P  0.0004). The two tests
performed similarly when the results were stratified by sepsis severity or infection site. Blood culture tended
to detect infections more frequently among patients who had previously received antibiotics (P  0.06).
Conversely, PCR identified an additional 24 organisms that blood culture failed to detect. Real-time multiplex
PCR has the potential to serve as an adjunct to conventional blood culture, adding diagnostic yield and
shortening the time to pathogen identification.
The emergency department (ED) often serves as the front
line for the initial evaluation and management of patients with
infections, with estimates indicating that there are more than
3.5 million visits to EDs annually (26). Community-acquired
sepsis carries a large health care burden and accounts for a
substantial proportion of these visits. Furthermore, recent
studies suggest a rising burden of sepsis, with the annualized
increase being about 8.7% (23). Many of these patients, esti-
mated at 3 per 1,000 population (1), progress to severe sepsis.
Despite improvements in the management of severe sepsis (15,
27), the case fatality rate ranges from 10% in children to 38.4%
in the elderly (1). However, sepsis case fatality rates can be
reduced by 33% to 77% with the early administration of ade-
quate antibiotics (4, 10, 17, 18, 34). The antibiotics initially
chosen are often broad and empirical, with modifications being
made after microbiological diagnostic information becomes
available. Blood culture remains the “gold standard” for the
identification of bacterial and fungal bloodstream infections,
although it is limited by high volume requirements to maximize
its sensitivity and often prolonged incubation times. In an ef-
fort to address some of these limitations, many advances have
been developed to improve the sensitivity and decrease the
time to identification of the cause of bloodstream infections.
Molecular amplification techniques have been developed to
replace the incubation step in blood culture. Conserved re-
gions of microbial genomes serve as targets for amplification,
such as the rRNA genes and the 16S-23S interspace region (13,
25). The identification of this species-specific amplified DNA is
coupled with one of a variety of detection schemes for the
rapid real-time identification of pathogen DNA in the blood-
stream. Many protocols that target individual species (8) or
multiple pathogens within a particular clade have been devel-
oped, such as panbacterial and panfungal assays (6, 12, 29).
Within the past year, the simultaneous detection of up to 25
common bacterial and fungal pathogens by the use of a mul-
tiplex real-time PCR format has been reported (19, 21, 22, 30,
32, 33). However, many of those studies defined operating
characteristics on the basis of repeated sampling of a small but
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highly morbid patient population, which can lead to spectrum
and context biases. We hypothesized that PCR and blood cul-
ture can identify a partially overlapping group of bloodstream
infections, making PCR a useful adjunct to blood culture. This
study aims to define the operating characteristics of the SeptiFast
multiplex real-time PCR assay compared to those of conven-
tional blood culture for the diagnosis of bloodstream infections
in patients with suspected community-acquired sepsis present-
ing to the ED.
MATERIALS AND METHODS
Study site and patients. Subjects were recruited from the Duke University
Medical Center ED (DUMC Level 1 Trauma Center, which has an annual
census of 65,000) and the Veterans Affairs Medical Center in Durham, NC
(DVAMC; which has an annual ED census of 40,000). This study was approved
by the institutional review board at each institution, and written, informed con-
sent was obtained from all study participants or their legal representatives.
Subjects were screened between July 2003 and February 2009. Patients were
considered for inclusion in the study if they had a known or suspected infection
on the basis of clinical data at the time of screening and if they exhibited two or
more signs of the systemic inflammatory response syndrome (SIRS) within a 24-h
period (3). Patients were excluded if they were 18 years old, if they had an
imminently terminal comorbid condition, or if they were participating in an
ongoing clinical trial. Only subjects admitted to the hospital and for whom blood
culture results were available were included in this analysis.
Data collection. Following the provision of informed consent, the patient or
the patient’s representative completed a standardized questionnaire that in-
cluded questions about demographic factors, recent exposures, and symptoms.
We obtained samples of blood for culture from all patients, but the samples for
culture from other anatomical sites were ordered by the treating physician, as
clinically indicated. Trained study coordinators at each site reviewed and ab-
stracted vital signs and the microbiology, laboratory, and imaging results from
the initial ED encounter and at 24-h intervals for up to 72 h or until death.
Following discharge from the hospital, research personnel abstracted the dura-
tion of hospitalization, the length of stay in an intensive care unit (ICU), the
in-hospital mortality rate, the timing and appropriateness of antimicrobial ad-
ministration, and microbiological culture results from the medical record.
Adjudication of infections and patient status. Research personnel blinded to
the hypothesis adjudicated the patient records at least 30 days after hospital
discharge in order to determine the discharge status, including the likelihood of
infection; the site of infection, if one was present; the causative organisms; and
the patient outcome. One of two study physicians with board certification in
emergency medicine (S.W.G.) or internal medicine (E.L.T.) determined the
infection status after a review of all study data and the complete patient medical
record, including ED dictations, hospital admission and discharge summaries,
and any other relevant information (e.g., consultant reports). The likelihood of
infection was categorized according to a five-point scale (11). Category 1 (con-
firmed) was defined as having clinical evidence of infection without evidence of
a noninfectious process and an identified etiologic agent. Category 2 (probable)
was the same as category 1 but in the absence of an identified etiologic agent.
Category 3 (possible) was reserved for indeterminate cases in which infection
could be neither confirmed nor excluded. Category 4 (negative) was defined as
no evidence of infection and no evidence of a noninfectious process. Finally,
category 5 (negative) was no evidence of infection and the identification of a
noninfectious etiology, which was required.
For patients who could not be definitively placed in an infection category by
the primary adjudicator (S.W.G.), a second individual with specialty training and
board certification in infectious diseases (C.W.W.) reviewed the medical record
and made the final determination. A third individual with specialty training in
infectious diseases (E.L.T.) performed an independent adjudication of a 10%
sample of the patient records. Agreement on the infection classification between
this individual and the primary adjudicator was high (kappa statistic  0.82; 95%
confidence interval [CI]  0.62 to 1.00). For determination of the infection
classification and the etiologic agents involved, investigators were blinded to the
multiplex PCR test results. The identification of blood culture contamination was
based on previously published criteria and included the probability that the
organism was a skin contaminant, the number of independent positive and
negative cultures, other concurrent microbiology results, and clinical compati-
bility (9, 31).
Study definitions. The severity of sepsis was determined on the basis of the
patient’s status at the time of study enrollment. Patients later determined not to
have infection (infection categories 4 and 5) were labeled as noninfected and
SIRS positive. Sepsis was defined as SIRS with evidence of infection but no
evidence of end-organ damage. Severe sepsis occurred in the presence of end-
organ damage, which included metabolic damage (a lactate concentration of
1.5 times the upper limit of normal or an arterial pH of 7.30), hematologic
damage (platelet count of 80,000/high-power field), pulmonary damage (intu-
bation or a partial arterial O2 concentration/fractional inspired O2 concentration
ratio, 250), or renal damage (urine output, 0.5 ml/kg of body weight/h,
despite adequate fluid resuscitation) (14, 24). Sepsis in the presence of hypoten-
sion (a systolic blood pressure of 90 mm Hg or a mean arterial pressure of 65
mm Hg), despite fluid challenge, or a blood lactate concentration of 4 mmol/
liter was defined as septic shock (14, 24).
Sample processing. Blood was collected for culture by the use of sterile
technique. The volume inoculated was not monitored and was subject to user
variability. At the Veterans Affairs Medical Center, the BacT/Alert system
(bioMérieux, Marcy l’Etiole, France) was used. At the Duke University Medical
Center, the BacT/Alert system was used along with the BD Bactec system
(Becton Dickinson and Company, Franklin Lakes, NJ). DNA was extracted by
use of a SeptiFast Lys kit on a MagNA Lyser platform (Roche Diagnostics),
followed by silica matrix purification. We performed multiplex PCR using the
LightCycler SeptiFast MGRADE test, version 2.0 (SeptiFast test; Roche, Basel,
Switzerland), an in vitro nucleic acid amplification test for the detection and
identification of DNA from bacterial and fungal microorganisms (see the
SeptiFast master list in Table 1). Internal controls for the amplification step are
included with the assay. Gram-positive and gram-negative organisms were tar-
geted via the internal transcribed spacer between the 16S and 23S rRNA genes,
whereas fungi were amplified by using the 18S and 5.8S rDNA sequence.
At the time of the initial ED visit, 1.5 ml of whole blood was drawn from each
subject and stored at 70°C at Duke University. Blood for experimental analysis,
including blood culture, was typically obtained within 120 to 180 min after the
initial clinical assessment. The frozen samples were later thawed and processed
TABLE 1. SeptiFast master list
























a Includes S. hominis subsp. novobiosepticus, S. pasteuri, S. warneri, S. cohnii
subsp. urealyticum, S. hominis subsp. hominis, S. lugdunensis, S. cohnii subsp.
cohnii, S. capitis subsp. ureolyticus, S. capitis subsp. capitis, S. caprae, S. sapro-
phyticus, S. saprophyticus subsp. saprophyticus, S. xylosus, S. epidermidis, and S.
haemolyticus.
b Includes S. agalactiae, S. anginosus, S. bovis, S. constellatus, S. cristatus, S.
gordonii, S. intermedius, S. milleri, S. mitis, S. mutans, S. oralis, S. parasanguinis,
S. pneumoniae, S. pyogenes, S. salivarius, S. sanguinis, S. thermophilus, S. vestibu-
laris, and S. viridans.
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according to the manufacturing guidelines and as published previously (19), and
negative and reagent controls were included. SeptiFast identification software
(SIS; version 1.1) was used to identify the organisms on the SeptiFast master list
by melting curve analysis. All tests were performed and all results were inter-
preted by a single research laboratory technician (D.J.) blinded to the hypothesis.
The processing time totaled about 6.5 h and consisted of 30 min for sample
thawing, 90 min for DNA extraction, 45 min for PCR setup, and 3.5 h for the
PCR itself, followed by 5 min for automated software analysis.
Statistical analysis. Unless otherwise specified, the frequency (percentage) is
reported for categorical variables, and mean (range) is presented for continuous
variables. For the purposes of defining the operating characteristics of the PCR,
we treated polymicrobial infections as a single event. In contrast, these polymi-
crobial isolates were counted as independent events and were analyzed qualita-
tively when the microbiology of PCR and blood culture were considered. The
area under the receiver operating characteristic curve (AUC) was determined as
previously recommended for binary test results (5). The time to blood culture
positivity among those subjects with concordant versus discordant blood culture
and PCR results was compared by using a two-sided t test. Comparison of the
blood culture and PCR results with respect to the likelihood of infection, the
severity of sepsis, the site of infection, and a history of antibiotic administration
was assessed by McNemar’s test. Statistical significance was set at a two-sided P
value of 0.05. The kappa statistic was calculated to measure the level of
agreement between blood culture and PCR results, where indicated. The likeli-
hood of infection was recoded into a dichotomous outcome (infection present
versus infection absent). “Infection present” comprised infection categories 1
(definite), 2 (probable), and 3 (possible). Infection categories 4 and 5 (no infec-
tion) defined the “infection absent” group. All analyses were performed with the
SAS (Cary, NC) program (version 9.2).
RESULTS
Subject characteristics. A total of 306 subjects were evalu-
ated by both conventional blood culture techniques and the
SeptiFast PCR. The demographic characteristics of the subject
population are presented in Table 2. Infection categories 1 and
2 together included those with clinically determined infections.
There were a combined 221 subjects in these two categories,
whereas 42 were identified as having a possible or unknown
infection (category 3) and 43 had no evidence of infection
(categories 4 and 5) (Table 2). The most common sites of
infection included the lung (n  55), urinary tract (n  46),
and skin (n  41), which together accounted for 66.0% of the
identifiable infection sites. Twenty-two different etiologic
agents were identified in 123 (40.2%) of the subjects, with the
remainder having no identified etiologic agent. However,
Staphylococcus aureus and Escherichia coli together accounted
for the majority (56.9%) of the etiologic agents identified. The
etiologic agents were identified by a variety of techniques,
including culture of blood, urine, sputum, or other specimens;
conventional PCR (e.g., for cytomegalovirus, Neisseria gonor-
rhoeae, Chlamydia trachomatis, etc.); antigen or serologic test-
ing (e.g., for Streptococcus pneumoniae urinary antigen); and
the use of special stains, among others, but without the use of
multiplex PCR.
Performance characteristics of PCR versus those of blood
culture. In order to define the performance characteristics of
PCR compared to those of blood culture, the likelihood of
infection was dichotomized. Infection categories 1 to 3 were
redefined as infection present, whereas infection categories 4
and 5 were redefined as infection absent (Table 3). By using
clinical criteria as the reference standard, blood culture had a
sensitivity of 0.25, a negative predictive value (NPV) of 0.18,
and an AUC of 0.63 (when the data for contaminants were
excluded). PCR had a sensitivity of 0.20, an NPV of 0.17, and
an AUC of 0.60. When the data for contaminants were in-
TABLE 2. Baseline demographic information for the 306
enrolled subjects
Characteristic Value
Mean (range) age 54.1 (18–97)






Mortality ............................................................................ 8 (2.6)
Length of stay (days)
Mean (range) .................................................................... 6.3 (1–111)
Median (IQRa) ................................................................. 4 (2–7)
No. (%) of subjects with the following:
Noninfected SIRS positive.............................................. 43 (14.1)
Sepsis .................................................................................184 (60.1)
Severe sepsis ..................................................................... 42 (13.7)
Septic shock ...................................................................... 37 (12.1)
No. (%) of subjects in the following
infection category:
1 (confirmed) ....................................................................127 (41.5)
2 (probable) ...................................................................... 94 (30.7)
3 (possible)........................................................................ 42 (13.7)
4 (negative) ....................................................................... 4 (1.3)
5 (negative) ....................................................................... 39 (12.7)
No. (%) of subjects with infection
at the following site:
Lung ................................................................................... 55 (18.0)
Urinary tract ..................................................................... 46 (15.0)
Skin .................................................................................... 41 (13.4)
Intra-abdominal ................................................................ 25 (8.2)
Intravascular catheter ...................................................... 16 (5.2)
Otherb ................................................................................ 32 (10.5)
Unknownc.......................................................................... 91 (29.7)
No. (%) of subjects infected with the
following etiologic agentd:
Staphylococcus aureus ...................................................... 42 (34.1)
Escherichia coli ................................................................. 28 (22.8)
Klebsiella pneumoniae/Klebsiella oxytoca ........................ 11 (8.9)
Streptococcus pneumoniae................................................ 9 (7.3)
Streptococcus species......................................................... 6 (4.9)
Cryptococcus neoformans ................................................. 2 (1.6)
Proteus mirabilis ................................................................ 2 (1.6)
Pseudomonas aeruginosa .................................................. 2 (1.6)
Other etiologic agentse .................................................... 21 (17.1)
Unidentified ......................................................................183
a IQR, interquartile range.
b Includes bone (n  9), central nervous system (n  8), ear-nose-throat (n 
7), gynecologic (n  6), and cardiac (n  2).
c Subjects in infection categories 4 and 5 are considered to have an “unknown”
site of infection.
d The percentage is based on the total number of etiologies identified. Each
etiologic agent was identified by conventional microbiological techniques but
excluding multiplex PCR.
e Other etiologic agents include one isolate each of Apophysomyces elegans,
Campylobacter jejuni/Campylobacter coli, Candida glabrata, Chlamydia trachoma-
tis, Clostridium difficile, cytomegalovirus, Enterobacter species, Enterococcus fae-
calis, Fusobacterium nucleatum, Haemophilus influenzae, herpes simplex virus,
influenza virus, Listeria monocytogenes, Morganella morganii, Neisseria gonor-
rhoeae, Peptostreptococcus species, Pneumocystis jirovecii, Rickettsia rickettsii, Sal-
monella enterica serovar Paratyphi, Serratia marcescens, and Staphylococcus spe-
cies (coagulase-negative staphylococcus).
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cluded in the analysis, the operating characteristics of blood
culture were essentially unchanged: a sensitivity of 0.32, a spec-
ificity of 0.95, an NPV of 0.19, a positive predictive value
(PPV) of 0.98, and an AUC of 0.64. No contaminants were
detected by PCR. When PCR and blood culture were used in
combination, the sensitivity was 0.30, the NPV was 0.19, and
the AUC was 0.65 (excluding the data for contaminants).
When blood culture was used as the reference standard, PCR
had a sensitivity of 0.61, a specificity of 0.95, an NPV of 0.90,
a PPV of 0.76, and an AUC of 0.78 (on the basis of the data for
noncontaminant blood culture isolates that were represented
on the PCR list in Table 1). The kappa statistic for the agree-
ment of the blood culture and PCR results for these subjects
was 0.59 (95% CI, 0.48 to 0.69).
Microbiological concordance/discordance. The distribution
of organisms identified by blood culture, PCR, or both meth-
ods is presented in Table 4. Statistical comparisons of the
blood culture and PCR results stratified by organism were
precluded by the relatively small number of results for any
given organism. Nevertheless, there are several noteworthy
observations. Many more contaminants were obtained by
blood culture (20 isolates for 19 subjects) than by PCR (no
contaminants). Fourteen of the blood culture contaminants
consisted of coagulase-negative staphylococci. The majority of
the Staphylococcus aureus isolates (17 of 24) were detected by
both blood culture and PCR, with only a few more isolates
added by either assay alone. This is in contrast to the results for
Streptococcus pneumoniae, for which the results of both assays
overlapped in only one case. Blood culture identified five
additional cases of S. pneumoniae bacteremia, whereas PCR
alone identified no additional cases. In cases in which the
blood culture result was positive but the PCR result was neg-
ative, we determined if the discordance was due to the failure
of the PCR, such as the inability of the primers to hybridize to
the target site. We therefore retrieved the isolates from the
cultures of blood from those subjects with a corresponding
negative PCR result. Addition of these isolates from the solid
culture media to the PCR resulted in positive results for the
specified organism in 18 of 19 cases, suggesting that the orig-
inally negative PCR result was not intrinsic to the reaction
itself. Finally, the specific probes used in this multiplex PCR
platform were designed to detect the most common pathogens
leading to nosocomial bloodstream infections. There were 26
different pathogens identified as causing bloodstream infec-
tions in this cohort, of which 20 are on the list of SeptiFast
PCR-detectable organisms (77%).
Of the 53 subjects with positive PCR results, 6 had polymi-
crobial infections, for the isolation of a total of 64 organisms
(Table 4). Of the 66 subjects with positive blood culture results
(excluding contaminants), 3 had polymicrobial infections, for a
total of 72 organisms. The lack of independence in identifying
polymicrobial infections precludes their inclusion in an analysis
of the test characteristics, as discussed in Materials and Meth-
ods. However, by taking these factors into account and exclud-
ing those blood culture isolates that are not on the PCR list,
the rate of discordance is equalized (24 blood culture-negative
and PCR-positive results versus 26 blood culture-positive and
PCR-negative results).
An overall comparison of the concordance between the
TABLE 3. Assay performance as a function of infection status,









Present Absent Positive Negative
Blood culture positive 66 0
Blood culture negative 197 43
PCR positive 53 0 40 13
PCR negative 210 43 26 227
Blood culture and/or PCR positive 79 0
Blood culture and PCR negative 184 43
a Blood culture and PCR results are presented separately, followed by perfor-
mance of a combined blood culture and PCR strategy. The performance of PCR
versus that of blood culture as the reference standard is also presented.
TABLE 4. Microorganisms identified by PCR and/or blood culturea
Microorganism








Staphylococcus aureus 17 2 5
Staphylococcus species (CoNS) 0 1 1
Streptococcus pneumoniae 1 0 5
Streptococcus species 1 1 2
Enterococcus faecalis 0 0 1
Enterococcus faecium 0 0 0








Proteus mirabilis 0 0 1
Pseudomonas aeruginosa 1 2 0
Serratia marcescens 1 1 0
Stenotrophomonas maltophilia 0 1 0
Fungal panel
Candida albicans 0 0 0
Candida glabrata 0 1 1
Candida krusei 0 1 0
Candida parapsilosis 0 0 0
Candida tropicalis 0 0 0
Aspergillus fumigatus 0 1 0
Contaminants
Staphylococcus species (CoNS) 0 0 14
Streptococcus species 0 0 2
Enterococcus faecalis 0 0 2
Bacillus (non-Bacillus anthracis) — — 1
Propionibacterium acnes — — 1
Not in PCR menu
Citrobacter amalonaticus — — 1
Fusobacterium species — — 1
Kluyvera species — — 1
Listeria monocytogenes — — 1
Peptostreptococcus species — — 1
Salmonella species — — 1
a BC, blood culture; CoNS, coagulase-negative Staphylococcus; —, organisms
not on the SeptiFast PCR-detectable master list.
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two tests is presented in Fig. 1A. Of the 40 subjects with
concordant positive results, blood culture and PCR identi-
fied the same etiologic organism in 38 cases. There were two
cases in which both assays were concordant positive but
were concordant for different organisms. In the first, Staph-
ylococcus aureus was detected by blood culture and Kleb-
siella pneumoniae/Klebsiella oxytoca was identified by PCR.
The patient involved in this case had an indwelling central
venous catheter in the femoral vein as well as osteonecrosis
of the femoral heads with a possible associated infection
(but the infection was not confirmed). The other case was a
patient with a left ventricular assist device who clinically had
a drive-line infection. PCR detected coagulase-negative
Staphylococcus, whereas blood culture and urine culture
detected Proteus mirabilis, considered to represent a coinci-
dent case of urinary tract infection.
The data in Fig. 1B expand on the issue of concordance by
treating each isolate from polymicrobial infections as a sepa-
rate event. Excluding contaminants and those organisms iso-
lated by blood culture that are not on the SeptiFast master list,
a total of 40 organisms were isolated by both assays. Blood
culture added an additional 26 isolates, 10 of which could be
confirmed by culture of other non-blood specimens (e.g., urine
culture). PCR added an additional 24 isolates, 4 of which could
be confirmed by culture of other non-blood specimens (termed
“concordant non-blood culture” in Fig. 1B).
Time to positivity. The time to blood culture positivity, de-
fined as the time from the start of incubation to the time of the
detection of growth in at least one blood culture, correlates
with the severity of sepsis and the burden of infection (2, 16,
20). We assessed whether the time to blood culture positivity,
as a proxy for the bacterial burden, correlated with the likeli-
hood of blood culture and PCR concordance and found no
significant difference. The mean time to positivity among those
subjects with concordant blood culture and PCR results was
23 h 15 min, whereas it was 26 h 12 min for subjects with
discordant blood culture and PCR results (a difference of 177
min; 95% CI, 583 to 936 min). Stratification by the Gram
stain result did not reveal any significant differences between
subjects with concordant and discordant results. The mean
time to positivity among those with concordant results and
gram-positive bacterial infections was 17 h 52 min, whereas it
was 26 h 11 min for those with discordant results and gram-
positive bacterial infections (a difference of 499 min; 95% CI,
516 to 1,514 min). The mean time to positivity for subjects
with concordant blood culture and PCR results and gram-
negative bacterial infections was 28 h 19 min, whereas it was
25 h 9 min for those with discordant results and gram-negative
bacterial infections (a difference of 190 min; 95% CI, 1,484
to 1,104 min).
TABLE 5. Performance of blood culture versus performance of













Category 1, definite (127)  40 26 74.8 (0.50)
 6 55
Category 2, probable (94)  0 0 94.7 (0)
 5 89
Category 3, possible (42)  0 0 95.2 (0)
 2 40
Category 4, negative (4)  0 0 100 (0)
 0 4
Category 5, negative (39)  0 0 100 (0)
 0 39
a For category 1, P  0.0004 by McNemar’s test for agreement between blood
culture and PCR stratified by infection category. McNemar’s test could not be
performed for categories 2 to 5 due to the absence of positive blood cultures.
FIG. 1. Positive and negative agreement of PCR and blood culture
(BC) results. (A) “Patient concordance” defines concordant positive as
a single subject with a positive blood culture result and a positive PCR
result but not necessarily for the same organism or number of organ-
isms. “Isolate concordance” defines concordant positive as a single
instance in which the same organism was isolated by blood culture and
PCR, which might occur more than once in a subject with a polymi-
crobial infection. Subjects with polymicrobial infections are counted
only once under patient concordance, but each isolate is counted
independently under isolate concordance, resulting in more isolates
than the total number of subjects. (B) Results of blood culture and
PCR reconciled with other available culture data. “Concordant non-
blood culture” represents instances in which some other microbiolog-
ical investigation (e.g., urine culture or antigen testing) identified the
same infectious etiology that PCR or blood culture did.
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Correlation with infection and sepsis severity. The results
were stratified by the five-level infection category scheme de-
fined in Materials and Methods and are presented in Table 5.
Among those patients with a definite infection, which was
determined on the basis of the blood culture data but blinded
with respect to the PCR results, blood culture was superior to
PCR (sensitivities, 0.52 and 0.36, respectively; P  0.0004).
Among the category 1 patients, the value of the kappa statistic
was 0.50 (95% CI, 0.35 to 0.65), correlating to a moderate
strength of agreement between blood culture and PCR. There
were two category 3 infections (possible infection) in which
PCR identified an organism. In one case, Serratia marcescens
was identified by PCR in a 33-year-old woman who presented
for the evaluation of fever, abdominal pain, and diarrhea after
having an indwelling vascular catheter accessed. The etiology
was never identified but was presumed to be gastroenteritis
rather than a line infection. She was empirically treated with
broad-spectrum antibiotics for the length of her 2-day hospi-
talization but was discharged without antibiotics. Her fol-
low-up care did not reveal any evidence of a recurrence. The
other case involved a 48-year-old man with increased drainage
from a surgical drain 3 weeks following pancreatectomy, sple-
nectomy, and cholecystectomy for chronic pancreatitis. PCR
identified Staphylococcus aureus, but blood cultures and drain
fluid cultures were negative.
The severity of sepsis was assessed for the subjects and was
stratified by the assay results (Table 6). By definition, subjects
in infection categories 4 and 5 did not have an infection and
were therefore classified as noninfected SIRS positive. The
majority of subjects with confirmed, probable, or possible in-
fections (n  263) met the criteria for sepsis (n  184, or 70%).
Forty-two (16%) subjects had severe sepsis, and 37 (14%) had
septic shock. Blood culture and PCR performed similarly
across sepsis severities. The value of the kappa statistic across
all sepsis severities was 0.58 (95% CI, 0.46 to 0.70), which
corresponds to a moderate strength of agreement between
blood culture and PCR.
Performance by site of infection. The site of infection was
determined for all subjects with definite, probable, or possible
infections. An overall distribution of the sites involved is pre-
sented in Table 2. The performance of blood culture compared
to that of PCR with respect to the adjudicated site of infection
was not significantly different for any site. However, it is note-
worthy that a majority of the subjects with infections of the
urinary tract (25 of 46) or infections due to intravascular cath-
eters (14 of 16) had a positive blood culture and/or a positive
PCR result. A majority of the subjects in all other infection site
categories had concordant negative blood culture and PCR
results (126 of 153).
Prior antibiotic exposure. Antibiotic administration can rap-
idly sterilize the bloodstream, whereas bacterial DNAemia
may persist. We evaluated the effect of prior antibiotic admin-
istration on the performance characteristics of blood culture
and PCR. There were 69 subjects (22.5% of 306) who received
at least one dose of antibiotic before blood was collected for
culture or PCR. Among those patients who did not previously
receive a dose of antibiotics, the performance characteristics of
blood culture and PCR were not statistically different. How-
ever, among the 69 patients who did previously receive antibi-
otics, blood culture alone was positive in 8 cases, PCR alone
was positive in 2 cases, and both assays were concordant pos-
itive in 5 cases (P  0.06).
DISCUSSION
Patients presenting to the ED with suspected sepsis can
follow a spectrum of clinical courses, ranging from prompt
resolution to substantial morbidity and death. Many factors
that help determine which trajectory a patient takes have been
identified. Vitally important to clinical recovery is the prompt
administration of appropriate antibiotics (4, 10, 17, 18, 34).
Currently, the initial choice of antibiotics is empirical and
broad and covers the most likely etiologic agents. The major
limitation to a more targeted antibiotic strategy is the lack of
an available diagnostic method for the rapid and reliable iden-
tification of the etiologic agent. Blood culture is the most
widely utilized technique for the diagnosis of bloodstream in-
fections. However, despite its high degree of specificity, its
sensitivity remains low and the mean time to positivity in our
study was approximately 24 h and reached nearly 5 days in
some cases. Antigen and serological testing is highly specific
but has great variations in sensitivity, depending on the tar-
geted organism. Furthermore, it is generally limited to a par-
ticular organism, and consequently, the suspected etiologic
agent must be specified a priori. This study aimed to evaluate
a real-time multiplex PCR assay as an adjunct to blood culture
for the rapid identification of bloodstream infections.
The findings of this study suggest a high degree of concor-
dance between the results of blood culture and PCR, with the
two methods having similar operating characteristics (sensitiv-
ities, 0.25 and 0.20, respectively). This is most evident among
those patients without infection and is manifested by high
specificities: 95% for blood culture and 100% for PCR (when
contaminants are included). Interestingly, of 127 subjects with
definite infections, 55 had concordant negative results, whereas
40 had concordant positive results, for overall agreement in
74.8% of cases. The remaining 32 discordant cases are repre-
sented by 26 blood culture-positive and PCR-negative results
and 6 blood culture-negative and PCR-positive results. Due to
TABLE 6. Performance of blood culture versus that of PCR















 0 0 100 (0)
 0 43
Sepsis (184)  23 17 85.9 (0.55)
 9 135
Severe sepsis (42)  9 5 83.3 (0.60)
 2 26
Septic shock (37)  8 4 83.8 (0.61)
 2 23
a For the sepsis group, P  0.12; for the severe sepsis group, P  0.26; for the
septic shock group, P  0.41. Statistical analysis for the noninfected SIRS-
positive group is not available due to the absence of positive blood cultures.
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the significant number of infections that would be missed, it
does not appear that this multiplex PCR assay could replace
blood culture for the identification of bloodstream infections in
patients presenting to the ED with suspected sepsis. However,
the time to the identification of the etiologic agent is clearly
much shorter with PCR than with blood culture. PCR also
added diagnostic yield, with PCR detecting an additional 24
isolates that were missed by blood culture. The clinical rele-
vance of such PCR-positive but blood culture-negative situa-
tions is an important question. Our results suggest that the
organisms identified by PCR alone were clinically relevant on
the basis of chart review and confirmation of the result by other
microbiological diagnostic methods, such as urine culture and
antigen testing. Potential reasons for the discordant results are
numerous. We were unable to ensure that an adequate volume
of blood for culture was collected, which could have contrib-
uted to the discordant blood culture-negative and PCR-posi-
tive results. Furthermore, the ability of PCR to detect DNA in
sterilized blood, such as after antibiotic administration, could
also have yielded these discordant results. However, an anal-
ysis of the PCR and blood culture results stratified by prior
antibiotic use did not support this hypothesis. In contrast, dis-
cordant blood culture-positive and PCR-negative results could
arise from the intrinsic variability of PCR, inhibiting factors
present in the patient sample or other unidentified factors.
The cases in which PCR identified an infection are those in
which the benefits of PCR can be most clearly realized. When
there is concordance between PCR and blood culture results,
the primary advantage to a PCR-based assay is the timeliness
with which those results are available compared to the time to
the availability of conventional blood culture results: 6 to 7 h
and 24 to 72 h, respectively. This may allow the treating phy-
sician to narrow antibiotic coverage early in the course of
treatment, potentially avoiding the toxicity and costs associated
with the use of broad and empirical antimicrobial therapy.
PCR can also identify an infection that was not being ade-
quately treated. For example, empirical antibiotic choices typ-
ically do not treat fungal infections. However, the identifica-
tion of fungemia by PCR can allow the physician to
appropriately expand the antimicrobial regimen early in the
course of disease. The potential clinical utility of the SeptiFast
PCR to effect the clinical treatment and outcome was not
addressed in this study, which used banked blood samples.
Nevertheless, our results affirm the hypothesis that PCR and
blood culture can identify a partially overlapping set of blood-
stream infections, making PCR a useful adjunct to blood cul-
ture. Prospective clinical trials for the assessment of treatment
and patient outcomes will be important to the further advance-
ment of a multiplex PCR approach.
This study has several strengths in comparison to some pre-
vious evaluations of this multiplex PCR platform. First, pa-
tients were recruited from the ED on the basis of a suspicion
of community-acquired sepsis. This relatively undifferentiated
patient group is in contrast to the patient populations used in
other studies, which enriched for patients with confirmed in-
fection or hospital inpatients, who are at particularly high risk
of developing bloodstream infections. Extrapolation of the
findings from those studies could otherwise lead to context and
spectrum biases. Furthermore, our use of blinded clinical ad-
judicators to determine infection status resulted in a better
classification system. As a result, 14% of patients in this study
were ultimately determined to have a noninfectious disease
process, serving as a valuable internal control.
Second, another significant strength of this study is the way
in which this new diagnostic tool was evaluated. Most pub-
lished reports evaluating the SeptiFast PCR platform have
tested multiple isolates from a small number of subjects, lead-
ing to spectrum bias, such that multiple samples are more
likely to be drawn for sicker patients and these patients are
subsequently more likely to have positive assay results (7, 22,
30, 32, 33). In contrast, our study is the largest to date in which
subjects were identified prospectively and samples were col-
lected from any given subject only once (21).
There are several potential limitations to this study. First,
patients were recruited from the EDs of two tertiary-care cen-
ters, and consequently, the results may not be applicable to
other clinical settings with different patient characteristics, re-
sources, and laboratory procedures. A second potential limi-
tation in interpreting the results of this study is the heteroge-
neity in the methods by which blood samples for culture were
drawn. Although there are specific guidelines for how blood
samples for culture should be drawn, including guidelines on
skin cleansing, the volume per bottle, and the number of bot-
tles, there is no way to ensure that all samples were collected
according to those guidelines. This can have implications both
for the sensitivity and for the specificity of blood culture, lead-
ing to an inadequate criterion bias, although it is more repre-
sentative of actual clinical practice. Furthermore, although in-
fection status is based on a multitude of factors, blood culture
results are part of the criterion standard. As a result, incorpo-
ration bias likely plays a role in our observation that blood
culture was statistically significantly better than PCR for those
patients with definite infections. In addition, our clinical adju-
dication of infection includes viral, rickettsial, and other infec-
tious etiologies that are expected to yield negative blood cul-
ture and PCR results, such as herpes simplex virus, influenza
virus, Rickettsia rickettsii, and Clostridium difficile. This would
tend to underestimate the performance characteristics of
blood culture and PCR when the clinical infection criterion is
used as the gold standard.
Current unanswered questions include the optimal assay
conditions needed to minimize PCR inhibition by substances
such as the heme in blood, the ethanol introduced during the
extraction process, and other unidentified inhibitors found in
blood (8, 28). In addition, the patient population most likely to
benefit from this diagnostic tool needs to be better defined.
Clinical utility may vary depending on the population preva-
lence of septicemia, with potentially lower levels being de-
tected in the ED setting than in the ICU setting. Finally, the
assays were performed with frozen samples and did not inform
actual clinical practice. To that end, a recent study by Dierkes
et al. reported on the effects of performing the SeptiFast-based
PCR in parallel with blood culture with samples from a cohort
of hospitalized patients (7). PCR was performed at the discre-
tion of treating physicians without any subject enrollment or
randomization, and the analysis was retrospective. Despite the
biases that this might introduce, their findings are largely con-
sistent with our own and serve as an important step toward
assessing the directed clinical application of this technology.
In summary, PCR is a promising tool for the rapid identifi-
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cation of bloodstream infections as an adjunct to blood culture.
Overall, the operating characteristics of PCR are similar to
those of blood culture for the diagnosis of infection, but a
significant number of additional isolates are identified by PCR.
High-quality research into the real-clinical-time application of
these results is a critical next step in the development of this
technology.
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